Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
Journal Title: Journal of Diabetes and Obesity - Year 2016, Vol 4, Issue 1
Abstract
Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese patients with type 2 diabetes. Material and Methods: This observational retrospective study included 47 patients with type 2 diabetes who were treated with liraglutide alone or in combination with sulfonylureas. Metformin was added at a dose ranging from 250 to 500 mg/day based on inadequate glycemic control. Liraglutide and metformin doses were converted from mg/day to mg/kg body weight/day before analysis of the correlation between the dose and changes in glycated hemoglobin (HbA1c) and body mass index (BMI). Results: Both HbA1c and BMI decreased significantly after 24 weeks of the combination treatment. Mild gastrointestinal adverse events were reported by 21% of the patients. Only the dose of metformin, but not that of liraglutide, expressed in mg/kg body weight was correlated significantly with decrease in HbA1c and BMI. Conclusions: The addition of metformin to the maximum permissible dose of liraglutide helps secure glycemic control and reduce BMI in Japanese patients with type 2 diabetes who exhibit inadequate response to liraglutide.
Authors and Affiliations
Masao Toyoda
Keywords
Related Articles
- EP ID EP417851
- DOI 10.15436/2376-0494.17.1300
- Views 109
- Downloads 0
Effect of Chromium(III) -Amino acid (1:3)Complexes on High Sucrose Induced Insulin Resistance, Lipid Abnormalities - Oxidative Stress in Male Sprague Dawley Rats
This study was carried out to assess the anti-hyperglycaemic effects if any of novel synthetic binary chromium (III)-amino acid complexes in a high sucrose (HS) induced insulin resistance (IR) and or impaired glucose tol...
Alstrom Syndrome with a Mutation in Exon8 (C.4746C > A) of Alstrom Syndrome Protein 1 Gene: The First Case Report and Literature Review
Alström syndrome (AS) is a rare, autosomal recessive disorder characterized by progressive cone-rod dystrophy, childhood obesity, sensorineural hearing impairment, type 2 diabetes, hypogonadism, and additional abnormalit...
Discovery of Adiponectin and its Future Prospect
Adiponectin is an adipocyte-specific protein abundantly present in the plasma. Since its discovery, numerous experimental and clinical studies have demonstrated that adiponectin has anti-atherogenic, antidiabetic and ant...
Herbal Anti-Hyperglycemic Compound Improves Glycemic Control and Insulin Sensitivity in Diabetic Rats
Objective: To study the effect of HPLC purified herbal anti-hyperglycemic active compound (FIIc) isolated from the fruit pulp of Eugenia jambolana in diabetic rats. Methods: 24 male wistar rats were taken and diabetes wa...
Fructose Intake and Circulating Triglycerides: An Examination of the Role of APOC 3
Fructose consumption can lead to marked increases in plasma triglycerides in both humans and laboratory animals. We have observed that overnight access to a 16% fructose solution can promote hypertriglyceridemia in rats....